Dr. Cohen on the Evolution of Antibodies in Lymphoma

Video

In Partnership With:

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the evolution of antibodies for the treatment of lymphoma.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, discusses the evolution of antibodies for the treatment of patients with lymphoma.

Hematologic oncologists have been utilizing antibodies like rituximab (Rituxan) for the management of patients with lymphoma for the last 20 years, Cohen says. For a while, there was a major focus on CD20 antibodies. Over the last few years, there has been intriguing research looking at new targets, as well as combining antibodies with chemotherapy through antibody-drug conjugates (ADC). Brentuximab vedotin (Adcetris) is FDA approved for patients with relapsed Hodgkin lymphoma and is also used in choice T-cell lymphoma subtypes, Cohen says.

Another emerging ADC in the lymphoma landscape is polatuzumab vedotin, which was discussed at the 2018 ASCO Annual Meeting. This targets CD79B, which is a common target in B-cell malignancies. This agent has shown promise in particularly aggressive subtypes of non—Hodgkin lymphoma.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD